Skip to main content
NCBI home page
The Texas Heart Institute Journal logoLink to The Texas Heart Institute Journal
. 1997;24(4):308–316.

Nitric oxide for the evaluation and treatment of pulmonary hypertension in congenital heart disease.

J P Kovalchin 1, A R Mott 1, K L Rosen 1, T F Feltes 1
PMCID: PMC325473  PMID: 9456484

Abstract

The use of inhaled nitric oxide as a selective pulmonary vasodilator has expanded to include patients with congenital heart disease and pulmonary hypertension. The therapeutic and diagnostic roles of inhaled nitric oxide offer additional alternatives and benefits to these patients with pulmonary hypertension, particularly in the postoperative setting. This article reviews the background, mechanism of action, toxicities, and current clinical applications of inhaled nitric oxide in the child with congenital heart disease and pulmonary hypertension.

Full text

PDF
308

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adatia I., Atz A. M., Jonas R. A., Wessel D. L. Diagnostic use of inhaled nitric oxide after neonatal cardiac operations. J Thorac Cardiovasc Surg. 1996 Nov;112(5):1403–1405. doi: 10.1016/S0022-5223(96)70166-6. [DOI] [PubMed] [Google Scholar]
  2. Albina J. E., Reichner J. S. Nitric oxide in inflammation and immunity. New Horiz. 1995 Feb;3(1):46–64. [PubMed] [Google Scholar]
  3. Allman K. G., Young J. D., Carapiet D., Stevens J. E., Ostman-Smith I., Archer L. N. Effects of oxygen and nitric oxide in oxygen on pulmonary arterial pressures of children with congenital cardiac defects. Pediatr Cardiol. 1996 Jul-Aug;17(4):246–250. doi: 10.1007/BF02524802. [DOI] [PubMed] [Google Scholar]
  4. Anderson T. J., Meredith I. T., Ganz P., Selwyn A. P., Yeung A. C. Nitric oxide and nitrovasodilators: similarities, differences and potential interactions. J Am Coll Cardiol. 1994 Aug;24(2):555–566. doi: 10.1016/0735-1097(94)90316-6. [DOI] [PubMed] [Google Scholar]
  5. Archer S. L., Huang J. M., Hampl V., Nelson D. P., Shultz P. J., Weir E. K. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7583–7587. doi: 10.1073/pnas.91.16.7583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Artman M., Parrish M. D., Boerth R. C., Boucek R. J., Jr, Graham T. P., Jr Short-term hemodynamic effects of hydralazine in infants with complete atrioventricular canal defects. Circulation. 1984 May;69(5):949–954. doi: 10.1161/01.cir.69.5.949. [DOI] [PubMed] [Google Scholar]
  7. Askew G. L., Finelli L., Genese C. A., Sorhage F. E., Sosin D. M., Spitalny K. C. Boilerbaisse: an outbreak of methemoglobinemia in New Jersey in 1992. Pediatrics. 1994 Sep;94(3):381–384. [PubMed] [Google Scholar]
  8. Baudouin S. V., Bath P., Martin J. F., Du Bois R., Evans T. W. L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. Br J Clin Pharmacol. 1993 Jul;36(1):45–49. doi: 10.1111/j.1365-2125.1993.tb05890.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Beghetti M., Habre W., Friedli B., Berner M. Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br Heart J. 1995 Jan;73(1):65–68. doi: 10.1136/hrt.73.1.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Berner M., Beghetti M., Spahr-Schopfer I., Oberhansli I., Friedli B. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. Am J Cardiol. 1996 Mar 1;77(7):532–535. doi: 10.1016/s0002-9149(97)89353-8. [DOI] [PubMed] [Google Scholar]
  11. Bevilacqua M. P., Nelson R. M. Selectins. J Clin Invest. 1993 Feb;91(2):379–387. doi: 10.1172/JCI116210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bixler T. J., Gott V. L., Gardner T. J. Reversal of experimental pulmonary hypertension with sodium nitroprusside. J Thorac Cardiovasc Surg. 1981 Apr;81(4):537–545. [PubMed] [Google Scholar]
  13. Bolotina V. M., Najibi S., Palacino J. J., Pagano P. J., Cohen R. A. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 1994 Apr 28;368(6474):850–853. doi: 10.1038/368850a0. [DOI] [PubMed] [Google Scholar]
  14. Borland C. D., Higenbottam T. W. A simultaneous single breath measurement of pulmonary diffusing capacity with nitric oxide and carbon monoxide. Eur Respir J. 1989 Jan;2(1):56–63. [PubMed] [Google Scholar]
  15. Buga G. M., Griscavage J. M., Rogers N. E., Ignarro L. J. Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res. 1993 Nov;73(5):808–812. doi: 10.1161/01.res.73.5.808. [DOI] [PubMed] [Google Scholar]
  16. Bush A., Busst C. M., Haworth S. G., Hislop A. A., Knight W. B., Corrin B., Shinebourne E. A. Correlations of lung morphology, pulmonary vascular resistance, and outcome in children with congenital heart disease. Br Heart J. 1988 Apr;59(4):480–485. doi: 10.1136/hrt.59.4.480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Chiodi H., Mohler J. G. Effects of exposure of blood hemoglobin to nitric oxide. Environ Res. 1985 Aug;37(2):355–363. doi: 10.1016/0013-9351(85)90116-1. [DOI] [PubMed] [Google Scholar]
  18. Cioffi W. G., Jr, Ogura H. Inhaled nitric oxide in acute lung disease. New Horiz. 1995 Feb;3(1):73–85. [PubMed] [Google Scholar]
  19. Cornfield D. N., Abman S. H. Inhalational nitric oxide in pulmonary parenchymal and vascular disease. J Lab Clin Med. 1996 Jun;127(6):530–539. doi: 10.1016/s0022-2143(96)90143-2. [DOI] [PubMed] [Google Scholar]
  20. Curran R. D., Mavroudis C., Backer C. L., Sautel M., Zales V. R., Wessel D. L. Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension. Ann Thorac Surg. 1995 Dec;60(6):1765–1771. doi: 10.1016/0003-4975(95)00812-8. [DOI] [PubMed] [Google Scholar]
  21. D'Ambra M. N., LaRaia P. J., Philbin D. M., Watkins W. D., Hilgenberg A. D., Buckley M. J. Prostaglandin E1. A new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacement. J Thorac Cardiovasc Surg. 1985 Apr;89(4):567–572. [PubMed] [Google Scholar]
  22. Damen J., Hitchcock J. F. Reactive pulmonary hypertension after a switch operation. Successful treatment with glyceryl trinitrate. Br Heart J. 1985 Feb;53(2):223–225. doi: 10.1136/hrt.53.2.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Dawson T. M., Dawson V. L. ADP-ribosylation as a mechanism for the action of nitric oxide in the nervous system. New Horiz. 1995 Feb;3(1):85–92. [PubMed] [Google Scholar]
  24. Day R. W., Lynch J. M., Shaddy R. E., Orsmond G. S. Pulmonary vasodilatory effects of 12 and 60 parts per million inhaled nitric oxide in children with ventricular septal defect. Am J Cardiol. 1995 Jan 15;75(2):196–198. doi: 10.1016/s0002-9149(00)80080-6. [DOI] [PubMed] [Google Scholar]
  25. De Feyter P. J., Kerkkamp H. J., de Jong J. P. Sustained beneficial effect of nifedipine in primary pulmonary hypertension. Am Heart J. 1983 Feb;105(2):333–334. doi: 10.1016/0002-8703(83)90539-2. [DOI] [PubMed] [Google Scholar]
  26. Foubert L., Fleming B., Latimer R., Jonas M., Oduro A., Borland C., Higenbottam T. Safety guidelines for use of nitric oxide. Lancet. 1992 Jun 27;339(8809):1615–1616. doi: 10.1016/0140-6736(92)91886-d. [DOI] [PubMed] [Google Scholar]
  27. Friedli B., Kidd B. S., Mustard W. T., Keith J. D. Ventricular septal defect with increased pulmonary vascular resistance. Late results of surgical closure. Am J Cardiol. 1974 Mar;33(3):403–409. doi: 10.1016/0002-9149(74)90323-3. [DOI] [PubMed] [Google Scholar]
  28. Frostell C., Fratacci M. D., Wain J. C., Jones R., Zapol W. M. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation. 1991 Jun;83(6):2038–2047. doi: 10.1161/01.cir.83.6.2038. [DOI] [PubMed] [Google Scholar]
  29. Furchgott R. F., Zawadzki J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980 Nov 27;288(5789):373–376. doi: 10.1038/288373a0. [DOI] [PubMed] [Google Scholar]
  30. Gaston B., Drazen J. M., Loscalzo J., Stamler J. S. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med. 1994 Feb;149(2 Pt 1):538–551. doi: 10.1164/ajrccm.149.2.7508323. [DOI] [PubMed] [Google Scholar]
  31. Gerlach H., Rossaint R., Pappert D., Falke K. J. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest. 1993 Aug;23(8):499–502. doi: 10.1111/j.1365-2362.1993.tb00797.x. [DOI] [PubMed] [Google Scholar]
  32. Goetzman B. W., Sunshine P., Johnson J. D., Wennberg R. P., Hackel A., Merten D. F., Bartoletti A. L., Silverman N. H. Neonatal hypoxia and pulmonary vasospasm: response to tolazoline. J Pediatr. 1976 Oct;89(4):617–621. doi: 10.1016/s0022-3476(76)80403-9. [DOI] [PubMed] [Google Scholar]
  33. Haworth S. G. Pulmonary vascular disease in different types of congenital heart disease. Implications for interpretation of lung biopsy findings in early childhood. Br Heart J. 1984 Nov;52(5):557–571. doi: 10.1136/hrt.52.5.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Hoffman J. I., Rudolph A. M., Heymann M. A. Pulmonary vascular disease with congenital heart lesions: pathologic features and causes. Circulation. 1981 Nov;64(5):873–877. doi: 10.1161/01.cir.64.5.873. [DOI] [PubMed] [Google Scholar]
  35. Houde C., Bohn D. J., Freedom R. M., Rabinovitch M. Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators. Br Heart J. 1993 Nov;70(5):461–468. doi: 10.1136/hrt.70.5.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Ignarro L. J., Buga G. M., Byrns R. E., Wood K. S., Chaudhuri G. Endothelium-derived relaxing factor and nitric oxide possess identical pharmacologic properties as relaxants of bovine arterial and venous smooth muscle. J Pharmacol Exp Ther. 1988 Jul;246(1):218–226. [PubMed] [Google Scholar]
  37. Journois D., Pouard P., Mauriat P., Malhère T., Vouhé P., Safran D. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects. J Thorac Cardiovasc Surg. 1994 Apr;107(4):1129–1135. [PubMed] [Google Scholar]
  38. Kanwar S., Kubes P. Nitric oxide is an antiadhesive molecule for leukocytes. New Horiz. 1995 Feb;3(1):93–104. [PubMed] [Google Scholar]
  39. Kinsella J. P., Neish S. R., Shaffer E., Abman S. H. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992 Oct 3;340(8823):819–820. doi: 10.1016/0140-6736(92)92687-b. [DOI] [PubMed] [Google Scholar]
  40. Kolpakov V., Gordon D., Kulik T. J. Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ Res. 1995 Feb;76(2):305–309. doi: 10.1161/01.res.76.2.305. [DOI] [PubMed] [Google Scholar]
  41. Mehta S., Stewart D. J., Langleben D., Levy R. D. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation. 1995 Sep 15;92(6):1539–1545. doi: 10.1161/01.cir.92.6.1539. [DOI] [PubMed] [Google Scholar]
  42. Meyrick B., Reid L. Ultrastructural findings in lung biopsy material from children with congenital heart defects. Am J Pathol. 1980 Dec;101(3):527–542. [PMC free article] [PubMed] [Google Scholar]
  43. Miller O. I., Celermajer D. S., Deanfield J. E., Macrae D. J. Very-low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart disease. J Thorac Cardiovasc Surg. 1994 Sep;108(3):487–494. [PubMed] [Google Scholar]
  44. Oda H., Kusumoto S., Nakajima T. Nitrosyl-hemoglobin formation in the blood of animals exposed to nitric oxide. Arch Environ Health. 1975 Sep;30(9):453–456. doi: 10.1080/00039896.1975.10666749. [DOI] [PubMed] [Google Scholar]
  45. Palmer R. M., Ferrige A. G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987 Jun 11;327(6122):524–526. doi: 10.1038/327524a0. [DOI] [PubMed] [Google Scholar]
  46. Pepke-Zaba J., Higenbottam T. W., Dinh-Xuan A. T., Stone D., Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991 Nov 9;338(8776):1173–1174. doi: 10.1016/0140-6736(91)92033-x. [DOI] [PubMed] [Google Scholar]
  47. Pietro D. A., LaBresh K. A., Shulman R. M., Folland E. D., Parisi A. F., Sasahara A. A. Sustained improvement in primary pulmonary hypertension during six years of treatment with sublingual isoproterenol. N Engl J Med. 1984 Apr 19;310(16):1032–1034. doi: 10.1056/NEJM198404193101606. [DOI] [PubMed] [Google Scholar]
  48. Rabinovitch M., Bothwell T., Hayakawa B. N., Williams W. G., Trusler G. A., Rowe R. D., Olley P. M., Cutz E. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest. 1986 Dec;55(6):632–653. [PubMed] [Google Scholar]
  49. Rabinovitch M., Haworth S. G., Castaneda A. R., Nadas A. S., Reid L. M. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation. 1978 Dec;58(6):1107–1122. doi: 10.1161/01.cir.58.6.1107. [DOI] [PubMed] [Google Scholar]
  50. Rabinovitch M. Morphology of the developing pulmonary bed: pharmacologic implications. Pediatr Pharmacol (New York) 1985;5(1):31–48. [PubMed] [Google Scholar]
  51. Roberts J. D., Jr, Chen T. Y., Kawai N., Wain J., Dupuy P., Shimouchi A., Bloch K., Polaner D., Zapol W. M. Inhaled nitric oxide reverses pulmonary vasoconstriction in the hypoxic and acidotic newborn lamb. Circ Res. 1993 Feb;72(2):246–254. doi: 10.1161/01.res.72.2.246. [DOI] [PubMed] [Google Scholar]
  52. Roberts J. D., Jr, Lang P., Bigatello L. M., Vlahakes G. J., Zapol W. M. Inhaled nitric oxide in congenital heart disease. Circulation. 1993 Feb;87(2):447–453. doi: 10.1161/01.cir.87.2.447. [DOI] [PubMed] [Google Scholar]
  53. Roberts J. D., Jr, Roberts C. T., Jones R. C., Zapol W. M., Bloch K. D. Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat. Circ Res. 1995 Feb;76(2):215–222. doi: 10.1161/01.res.76.2.215. [DOI] [PubMed] [Google Scholar]
  54. Roberts J. D., Polaner D. M., Lang P., Zapol W. M. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992 Oct 3;340(8823):818–819. doi: 10.1016/0140-6736(92)92686-a. [DOI] [PubMed] [Google Scholar]
  55. Rossaint R., Falke K. J., López F., Slama K., Pison U., Zapol W. M. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993 Feb 11;328(6):399–405. doi: 10.1056/NEJM199302113280605. [DOI] [PubMed] [Google Scholar]
  56. Royall J. A., Kooy N. W., Beckman J. S. Nitric oxide-related oxidants in acute lung injury. New Horiz. 1995 Feb;3(1):113–122. [PubMed] [Google Scholar]
  57. Springer T. A. Adhesion receptors of the immune system. Nature. 1990 Aug 2;346(6283):425–434. doi: 10.1038/346425a0. [DOI] [PubMed] [Google Scholar]
  58. Szabó C. Alterations in nitric oxide production in various forms of circulatory shock. New Horiz. 1995 Feb;3(1):2–32. [PubMed] [Google Scholar]
  59. Twort C. H., van Breemen C. Cyclic guanosine monophosphate-enhanced sequestration of Ca2+ by sarcoplasmic reticulum in vascular smooth muscle. Circ Res. 1988 May;62(5):961–964. doi: 10.1161/01.res.62.5.961. [DOI] [PubMed] [Google Scholar]
  60. Wessel D. L., Adatia I. Clinical applications of inhaled nitric oxide in children with pulmonary hypertension. Adv Pharmacol. 1995;34:475–504. doi: 10.1016/s1054-3589(08)61104-7. [DOI] [PubMed] [Google Scholar]
  61. Wessel D. L., Adatia I., Giglia T. M., Thompson J. E., Kulik T. J. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation. 1993 Nov;88(5 Pt 1):2128–2138. doi: 10.1161/01.cir.88.5.2128. [DOI] [PubMed] [Google Scholar]
  62. Wheller J., George B. L., Mulder D. G., Jarmakani J. M. Diagnosis and management of postoperative pulmonary hypertensive crisis. Circulation. 1979 Dec;60(7):1640–1644. doi: 10.1161/01.cir.60.7.1640. [DOI] [PubMed] [Google Scholar]
  63. Winberg P., Lundell B. P., Gustafsson L. E. Effect of inhaled nitric oxide on raised pulmonary vascular resistance in children with congenital heart disease. Br Heart J. 1994 Mar;71(3):282–286. doi: 10.1136/hrt.71.3.282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Yoshida K., Kasama K. Biotransformation of nitric oxide. Environ Health Perspect. 1987 Aug;73:201–205. doi: 10.1289/ehp.8773201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Zapol W. M., Rimar S., Gillis N., Marletta M., Bosken C. H. Nitric oxide and the lung. Am J Respir Crit Care Med. 1994 May;149(5):1375–1380. doi: 10.1164/ajrccm.149.5.8173780. [DOI] [PubMed] [Google Scholar]

Articles from Texas Heart Institute Journal are provided here courtesy of Texas Heart Institute

RESOURCES